interferons

In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.

感染者中，重叠感染隐匿性HBV会影响干扰的疗效。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并硬化的慢性（CHC）患者接受α干扰包括派罗欣治疗时存功能失代偿和死亡风险。